Introduction: Treatment of rectal adenocarcinoma involves multi-disciplinary approach which includes radiation, surgery and chemotherapy. Our study aims to assess the clinical outcomes of patients with rectal adenocarcinoma treated in a tertiary care centre in South India.Materials and methods: A retrospective content-based analysis was made of ۱۳۱ patients diagnosed and treated for adenocarcinoma rectum in a tertiary care hospital during the period of ۱st January ۲۰۱۴ to ۳۱st December ۲۰۱۵. The primary objectives were to assess disease‑free survival (DFS) and overall survival (OS).Results: Of the ۱۳۱ patients, ۸۲ were males and ۴۹ were females with a median age of ۵۹ years. Stage II and Stage III disease together contributed to ۶۵.۶% of study population. After a median follow up of ۱۰۵.۸ months, the ۸-year overall survival (OS) and disease-free survival (DFS) were found to be ۷۷.۲% and ۷۸.۸% respectively. In the univariate analysis, stage of the disease and histology were found to be significant factors in determining the overall survival (p<۰.۰۵). Multivariate analysis showed poorly differentiated adenocarcinoma emerged as significant factor affecting overall survival. About ۳۱ (۲۳.۶%) patients showed disease recurrence. Of the ۳۱ patients, pelvic recurrence occurred in ۲۶% patients and among the distant metastases, liver was the most common site (۳۳%) followed by lung (۲۲%).Conclusion: The disease free survival and overall survival of our patients were comparable with the available published data.Introduction: Treatment of rectal adenocarcinoma involves multi-disciplinary approach which includes radiation, surgery and chemotherapy. Our study aims to assess the clinical outcomes of patients with rectal adenocarcinoma treated in a tertiary care centre in South India. Materials and methods: A retrospective content-based analysis was made of ۱۳۱ patients diagnosed and treated for adenocarcinoma rectum in a tertiary care hospital during the period of ۱st January ۲۰۱۴ to ۳۱st December ۲۰۱۵. The primary objectives were to assess disease‑free survival (DFS) and overall survival (OS). Results: Of the ۱۳۱ patients, ۸۲ were males and ۴۹ were females with a median age of ۵۹ years. Stage II and Stage III disease together contributed to ۶۵.۶% of study population. After a median follow up of ۱۰۵.۸ months, the ۸-year overall survival (OS) and disease-free survival (DFS) were found to be ۷۷.۲% and ۷۸.۸% respectively. In the univariate analysis, stage of the disease and histology were found to be significant factors in determining the overall survival (p<۰.۰۵). Multivariate analysis showed poorly differentiated adenocarcinoma emerged as significant factor affecting overall survival. About ۳۱ (۲۳.۶%) patients showed disease recurrence. Of the ۳۱ patients, pelvic recurrence occurred in ۲۶% patients and among the distant metastases, liver was the most common site (۳۳%) followed by lung (۲۲%). Conclusion: The disease free survival and overall survival of our patients were comparable with the available published data.
